Roche Holding AG banner

Roche Holding AG
OTC:RHHBF

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
OTC:RHHBF
Watchlist
Price: 419.5 USD Market Closed
Market Cap: $334.4B

P/OCF

13.7
Current
16%
More Expensive
vs 3-y average of 11.8

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
13.7
=
Market Cap
$279.8B
/
Operating Cash Flow
CHf18.9B

Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.

P/OCF
13.7
=
Market Cap
$279.8B
/
Operating Cash Flow
CHf18.9B

Valuation Scenarios

Roche Holding AG is trading above its 3-year average

If P/OCF returns to its 3-Year Average (11.8), the stock would be worth $362.17 (14% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-14%
Maximum Upside
+5%
Average Downside
5%
Scenario P/OCF Value Implied Price Upside/Downside
Current Multiple 13.7 $419.5
0%
3-Year Average 11.8 $362.17
-14%
5-Year Average 12.6 $384.5
-8%
Industry Average 14.4 $440.66
+5%
Country Average 13.1 $400.89
-4%

Forward P/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward P/OCF

Peer Comparison

All Multiples
P/OCF
P/E
All Countries
Close

Market Distribution

In line with most companies in Switzerland
Percentile
65th
Based on 939 companies
65th percentile
17.7
Low
0 — 8.4
Typical Range
8.4 — 19.1
High
19.1 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 8.4
Median 13.1
70th Percentile 19.1
Max 654.7

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

RHHBF Intrinsic Value
543.09 USD
Undervaluation 23%
Intrinsic Value
Price $419.5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett